EYE201 for Eye Conditions
What You Need to Know Before You Apply
What is the purpose of this trial?
EYE-TIE-201 is a 2-part study to investigate the safety and effectiveness of a new drug being developed called EYE201.All participants in the study will receive a total of 3 injections of EYE201 into the study eye, spaced at 4 weeks apart.In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of EYE201 will be assessed at increasing doses in branch retinal vein occlusion (BRVO) participants. Approximately 12 participants will be entered in this part of the study.In the second part of the study, called the dose finding part, 2 doses of EYE201 will be selected and their effectiveness will be compared. This portion of the study assesses the safety and preliminary efficacy of EYE201 in patients with diabetic macular edema (DME) or neovascular macular degeneration (NVAMD). Approximately 80 participants will be entered in this part of the study.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.
Are You a Good Fit for This Trial?
This trial is for individuals with macular edema following branch retinal vein occlusion, diabetic macular edema, or neovascular age-related macular degeneration. Participants will receive three injections of a new drug called EYE201 into the affected eye.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Multiple Ascending Dose (MAD) Study
Participants with macular edema following BRVO receive ascending doses of EYE201 to assess safety
Dose-finding Study
Participants with DME or NVAMD receive selected doses of EYE201 to assess safety and preliminary efficacy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- EYE201
Find a Clinic Near You
Who Is Running the Clinical Trial?
EyeBiotech Ltd.
Lead Sponsor